The ITGA1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the A-549 human lung adenocarcinoma epithelial cell line, featuring targeted disruption of the ITGA1 gene. This heterogeneous cell pool lacks integrin alpha-1 subunit expression, providing a versatile loss-of-function model for studying ??1??1 integrin biology. The polyclonal composition captures a broad spectrum of mutations without clonal bias, ensuring robust representation of knockout effects. CRISPR/Cas9-mediated gene disruption eliminates surface ??1 integrin, enabling investigation of ??1??1-dependent processes in a relevant epithelial context.
The parental A-549 line originates from a human lung carcinoma and retains key features of alveolar type II pneumocytes, including tight junction formation and surfactant secretion. These adherent epithelial cells are widely used to model non-small cell lung cancer, drug resistance, and pulmonary fibrosis due to their genetic tractability and suitability for high-content imaging and biochemical assays. The lung adenocarcinoma background makes A-549 cells particularly appropriate for examining integrin function in tumor progression and stromal interactions.
The ITGA1 gene encodes the alpha-1 integrin subunit, which pairs with ??1 to form the ??1??1 heterodimer, a receptor for collagen types I/IV and laminin. Ligand engagement activates FAK and Src, leading to phosphorylation of PI3K, Akt, and ERK1/2. Upstream regulators TGF-??1, TNF-??, IL-1??, and hypoxia control ITGA1 expression during tissue remodeling. The complex interacts with talin, vinculin, and kindlin to stabilize adhesions. ITGA1 disruption abolishes ??1??1 expression, impairing adhesion to collagen and reducing FAK/Akt phosphorylation, thereby altering migration, proliferation, and survival.
In the A-549 lung adenocarcinoma model, ITGA1 knockout enables precise dissection of ??1??1 integrin contributions to cancer cell behavior and fibrotic responses. Loss of ??1??1 is predicted to reduce adhesion to collagen-rich extracellular matrix, potentially affecting tumor cell dissemination and metastatic colonization. The alveolar type II-like phenotype of A-549 cells further permits investigation of integrin signaling in idiopathic pulmonary fibrosis, where aberrant collagen deposition and myofibroblast activation are driving events. Moreover, this knockout facilitates studies on compensatory integrin networks or crosstalk with growth factor receptors such as EGFR in the absence of the dominant collagen receptor.
Typical applications include Western blotting and RT-qPCR to confirm ITGA1 ablation, adhesion assays on collagen type I or IV, Boyden chamber migration assays, and phospho-specific detection of FAK (Y397) and Akt (S473) via immunoblotting or flow cytometry for integrin ??1 surface analysis. Researchers can employ this model to validate collagen-receptor signaling contributions to PI3K-Akt or MAPK pathway activation under stimuli like TGF-??1 or hypoxia. It is also suitable for drug target validation studies aimed at modulating integrin-mediated adhesion in lung cancer or fibrosis. For additional information or technical support, please contact Ascent Research.
